News
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...
The demand for the widely used cancer drug Taxol is increasing, but it's difficult and expensive to produce because it hasn't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback